Abstract：Objective To explore the clinical value of combined detection of Epstein-Barr virus antibodies, EA-IgA,VCA-IgA, and Rta-IgG in serum in the early screening and serodiagnosis of nasopharyngeal carcinoma (NPC). Methods We collected serum samples and clinical data from 264 NPC patients at first-time consultancy and 264 health examinees in 2019. Enzyme-linked immunosorbent assay (ELISA) was used to determine the levels of serum EA-IgA, VCA-IgA and Rta-IgG antibodies, and the values of the above-mentioned indicators in the diagnosis of NPC were evaluated. Results The sensitivity and specificity of EA-IgA, VCA-IgA and Rta-IgG antibodies in the diagnosis of NPC while detecting solely were 57.20% and 98.11%, 47.35% and 97.35%, 75.38% and 96.21%, respectively. Among them, the sensitivity of Rta-IgG antibody was the highest, and its specificity was better. The serological levels or positive rates of the three antibodies in the newly-diagnosed NPC group were significantly higher than those in the healthy control group, showing statistically significant differences (all P<0.05). In the combined detection and diagnosis of NPC, the sensitivity of combinations of EA-IgA+VCA-IgA+Rta-IgG antibodies was the highest (92.05%), with the largest AUC area (0.946), the highest negative predictive value (92.02%), the lowest omission rate (7.95%) and better specificity (91.67%). The positive rates of EA-IgA, VCA-IgA and Rta-IgG antibodies had no significant correlation with gender, age, clinical stage and tumor-node-metastasis (TNM) stage (all P>0.05). Conclusions The combined detection of EA-IgA+VCA-IgA+Rta-IgG antibodies has higher clinical value for early screening and diagnosis of NPC.
2021, Vol. 28 
